News
BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute
BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy candidates. Analysts say the M&A deal is a way to essentially settle out of court the ongoing mRNA patent dispute between the companies following some recent CureVac legal wins.
Multiple new members have voiced anti-vaccine views that are not based in scientific evidence. Their actions could shape the ...
Moderna is suing Pfizer and BioNTech, accusing the companies of infringing on Moderna’s patents when they partnered to develop their own COVID-19 vaccine. Moderna is suing Pfizer and ...
German pharmaceutical firm BioNTech, one of the first companies worldwide to develop an effective coronavirus vaccine, is looking to acquire its domestic rival CureVac, the firm said on Thursday.
S hares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback